Literature DB >> 23319253

[Primary curative radiochemotherapy in nasopharyngeal carcinomas. Cumulative total cisplatin dose of prognostic significance].

H Christiansen1, H A Wolff.   

Abstract

Entities:  

Year:  2013        PMID： 23319253     DOI： 10.1007/s00066-012-0285-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Herbert H Loong; Brigette B Y Ma; Sing-Fai Leung; Frankie Mo; Edwin P Hui; Michael K Kam; Stephen L Chan; Brian K H Yu; Anthony T C Chan
Journal:  Radiother Oncol       Date:  2012-01-31       Impact factor: 6.280

2.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

3.  Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH).

Authors:  Rolf Mertens; Bernd Granzen; Lisa Lassay; Peter Bucsky; Manfred Hundgen; Gunter Stetter; Gerhard Heimann; Claudia Weiss; Clemens F Hess; Gunther Gademann
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

4.  Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.

Authors:  Harold Lau; Sony Brar; Desiree Hao; Jack MacKinnon; Don Yee; Stefan Gluck
Journal:  Head Neck       Date:  2006-03       Impact factor: 3.147

5.  Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.

Authors:  Martina Buehrlen; Christian Michel Zwaan; Bernd Granzen; Lisa Lassay; Peter Deutz; Peter Vorwerk; Gundula Staatz; Günther Gademann; Hans Christiansen; Foppe Oldenburger; Miriam Tamm; Rolf Mertens
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

6.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

7.  Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.

Authors:  Dirk Rades; Fabian Fehlauer; Mashid Sheikh-Sarraf; Nadja Kazic; Hiba Basic; Robert Poorter; Samer G Hakim; Steven E Schild; Juergen Dunst
Journal:  Head Neck       Date:  2008-02       Impact factor: 3.147

8.  Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis.

Authors:  Diana Steinmann; Bettina Cerny; Johann Hinrich Karstens; Michael Bremer
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

9.  Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas.

Authors:  Hendrik Andreas Wolff; Ralph M W Rödel; Bastian Gunawan; Tobias Overbeck; Markus K A Herrmann; Steffen Hennies; Andrea Hille; Hilke Vorwerk; Christoph Matthias; Clemens F Hess; Hans Christiansen
Journal:  J Cancer Res Clin Oncol       Date:  2009-07-18       Impact factor: 4.553

10.  Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer.

Authors:  Hendrik Andreas Wolff; Tobias Overbeck; Ralph M Roedel; Robert M Hermann; Markus K A Herrmann; Tereza Kertesz; Hilke Vorwerk; Andrea Hille; Christoph Matthias; Clemens F Hess; Hans Christiansen
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-24       Impact factor: 4.553
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.